Ig Vena (Human Normal Immunoglobulin)

Human Normal Immunoglobulin, the active ingredient in Ig Vena, is an immunoglobulin presented as a solution for injection for intravenous use. It treats primary and secondary immunodeficiency diseases and other immune‑mediated conditions in patients with deficient or dysfunctional endogenous immunoglobulins.

GNH USA supplies Ig Vena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ig Vena is an intravenous immunoglobulin used to replace deficient antibodies in various immune disorders. - Primary immunodeficiency diseases: provides IgG replacement to reduce infection frequency and severity. - Secondary immunodeficiency: restores antibody levels in patients with acquired immune deficiency. - Idiopathic thrombocytopenic purpura: modulates immune response to increase platelet counts. - Kawasaki disease: reduces inflammation and coronary artery complications. - Chronic inflammatory demyelinating polyneuropathy: improves nerve function and reduces relapse rates.

Adverse reactions may occur with Ig Vena administration.

Common Side Effects: - Headache: mild to moderate intensity during or after infusion. - Fever and chills: transient rise in body temperature. - Nausea or vomiting: gastrointestinal discomfort. - Fatigue: feeling of tiredness post‑infusion.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Thromboembolic events: clot formation in veins or arteries. - Acute renal failure: sudden loss of kidney function, especially in high‑risk patients. - Aseptic meningitis: inflammation of the meninges without infection. - Hemolysis: destruction of red blood cells leading to anemia.

Before initiating Ig Vena therapy, consider the following precautions. - Screen for IgA deficiency: patients with anti‑IgA antibodies may experience severe reactions. - Assess renal function: monitor creatinine in patients with pre‑existing renal disease. - Monitor for thromboembolic risk: consider prophylaxis in high‑risk patients. - Observe for infusion reactions: start at a low rate and increase gradually. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ig Vena may interact with other medicines; review the following.

Major Interactions (Avoid): - Live vaccines: may reduce vaccine efficacy and increase infection risk. - Concurrent use of other immunoglobulin products: may cause immunoglobulin overload. - C1 esterase inhibitor concentrate: risk of hyperviscosity.

Moderate Interactions (Monitor Closely): - Anticoagulants: may increase bleeding risk due to volume load. - Diuretics: may affect fluid balance and blood pressure. - Renally toxic drugs (e.g., aminoglycosides): monitor renal function closely.